Medindia LOGIN REGISTER
Medindia
Advertisement

Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes

Monday, August 12, 2019 Research News
Advertisement
Background and objectives Data from observational and interventional studies provide discordant results regarding the relationship between creatinine increase after renin-angiotensin system inhibition (RASi) and adverse outcomes. We compared health outcomes among patients with different categories of increase in creatinine upon initiation of RASi in a large population-based cohort.
Advertisement

Design setting participants & measurements We performed a retrospective analysis of the Stockholm CREAtinine Measurements database which contains complete information on diagnoses medication dispensation claims and laboratory test results for all Stockholm citizens accessing health care. Included were 31951 adults initiating RASi during 2007–2011 with available pre- and postinitiation creatinine monitoring. Multivariable Cox regression was used to compare mortality cardiovascular and ESKD events among individuals with different ranges of creatinine increases within 2 months after starting treatment.
Advertisement

Results In a median follow-up of 3.5 years acute increases in creatinine were associated with mortality (3202 events) in a graded manner: compared with creatinine increases <10% a 10%–19% increase showed an adjusted hazard ratio (HR) of 1.15 (95% confidence interval [95% CI] 1.05 to 1.27); HR 1.22 (95% CI 1.07 to 1.40) for 20%–29%; HR 1.55 (95% CI 1.36 to 1.77) for ≥30%. Similar graded associations were present for heart failure (2275 events P<0.001) and ESKD (52 events; P<0.001) and less consistently myocardial infarction (842 events P=0.25). Results were robust across subgroups among continuing users when patients with decreases in creatinine were excluded from the reference group and after accounting for death as a competing risk.

Conclusions Among real-world monitored adults increases in creatinine (>10%) after initiation of RASi are associated with worse health outcomes. These results do not address the issue of discontinuation of RASi when plasma creatinine increases but do suggest that patients with increases in creatinine have higher subsequent risk of cardiovascular and kidney outcomes.
Sponsored Post and Backlink Submission


Latest Press Release on Research News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close